Serum levels of BAFF, but not APRIL, are increased after rituximab treatment in patients with primary Sjogren's syndrome: data from a placebo-controlled clinical trial.

@article{Pollard2013SerumLO,
  title={Serum levels of BAFF, but not APRIL, are increased after rituximab treatment in patients with primary Sjogren's syndrome: data from a placebo-controlled clinical trial.},
  author={Rodney P E Pollard and Wayel H. Abdulahad and A Vissink and Nishath Hamza and J. G. M. Burgerhof and Jiska M. Meijer and A Willemien Visser and Minke G. Huitema and Frederik K. L. Spijkervet and Cees G. M. Kallenberg and Hendrika Bootsma and Frans G. M. Kroese},
  journal={Annals of the rheumatic diseases},
  year={2013},
  volume={72 1},
  pages={146-8}
}
Citation for published version (APA): Pollard, R. P. E., Abdulahad, W. H., Vissink, A., Hamza, N., Burgerhof, J. G. M., Meijer, J. M., ... Kroese, F. G. M. (2013). Serum levels of BAFF, but not APRIL, are increased after rituximab treatment in patients with primary Sjogren's syndrome: data from a placebo-controlled clinical trial. Annals of the Rheumatic Diseases, 72(1), 146-148. DOI: 10.1136/annrheumdis-2012-202071